title: A Two-Day Continuous Nicotine Infusion Is Sufficient to Demonstrate Nicotine Withdrawal in Rats as Measured Using Intracranial Self-Stimulation.
abstract: Avoidance of the negative affective (emotional) symptoms of nicotine withdrawal (e.g., anhedonia, anxiety) contributes to tobacco addiction. Establishing the minimal nicotine exposure conditions required to demonstrate negative affective withdrawal signs in animals, as well as understanding moderators of these conditions, could inform tobacco addiction-related research, treatment, and policy. The goal of this study was to determine the minimal duration of continuous nicotine infusion required to demonstrate nicotine withdrawal in rats as measured by elevations in intracranial self-stimulation (ICSS) thresholds (anhedonia-like behavior). Administration of the nicotinic acetylcholine receptor antagonist mecamylamine (3.0 mg/kg, s.c.) on alternate test days throughout the course of a 2-week continuous nicotine infusion (3.2 mg/kg/day via osmotic minipump) elicited elevations in ICSS thresholds beginning on the second day of infusion. Magnitude of antagonist-precipitated withdrawal did not change with further nicotine exposure and mecamylamine injections, and was similar to that observed in a positive control group receiving mecamylamine following a 14-day nicotine infusion. Expression of a significant withdrawal effect was delayed in nicotine-infused rats receiving mecamylamine on all test days rather than on alternate test days. In a separate study, rats exhibited a transient increase in ICSS thresholds following cessation of a 2-day continuous nicotine infusion (3.2 mg/kg/day). Magnitude of this spontaneous withdrawal effect was similar to that observed in rats receiving a 9-day nicotine infusion. Our findings demonstrate that rats exhibit antagonist-precipitated and spontaneous nicotine withdrawal following a 2-day continuous nicotine infusion, at least under the experimental conditions studied here. Magnitude of these effects were similar to those observed in traditional models involving more prolonged nicotine exposure. Further development of these models, including evaluation of more clinically relevant nicotine dosing regimens and other measures of nicotine withdrawal (e.g., anxiety-like behavior, somatic signs), may be useful for understanding the development of the nicotine withdrawal syndrome.
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, MN, United States of America.|Department of Ecology, Evolution, and Behavior, University of Minnesota, Minneapolis, MN, United States of America.
authors.forename: Peter
authors.initials: P
authors.lastname: Muelken
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, MN, United States of America.|Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States of America.
authors.forename: Clare E
authors.initials: CE
authors.lastname: Schmidt
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, MN, United States of America.
authors.forename: David
authors.initials: D
authors.lastname: Shelley
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, MN, United States of America.
authors.forename: Laura
authors.initials: L
authors.lastname: Tally
authors.affiliation: Minneapolis Medical Research Foundation, Minneapolis, MN, United States of America.|Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States of America.|Department of Psychology, University of Minnesota, Minneapolis, MN, United States of America.
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Harris
mesh_terms: D000818:Animals; D007262:Infusions, Intravenous; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D009538:Nicotine / Q000008:administration & dosage* / Q000494:pharmacology*; D017208:Rats, Wistar; D012653:Self Stimulation; D013375:Substance Withdrawal Syndrome / Q000473:pathology*
chemical_list: D008464:Mecamylamine; D009538:Nicotine